Multifunctional mesoporous silica nanospheres with cleavable Gd(III) chelates as MRI contrast agents: synthesis, characterization, target-specificity, and renal clearance.

Mesoporous silica nanospheres (MSNs) are a promising material for magnetic resonance imaging (MRI) contrast agents. In this paper multifunctional MSNs with cleavable Gd(III) chelates are synthesized and characterized, and their applicability as MRI contrast agents is demonstrated both in vitro and in vivo. The MSNs contain Gd(III) chelates that are covalently linked via a redox-responsive disulfide moiety. The MSNs are further functionalized with polyethylene glycol (PEG) and an anisamide ligand to improve their biocompatibility and target specificity. The effectiveness of MSNs as an MRI imaging contrast agent and their targeting ability are successfully demonstrated in vitro using human colon adenocarcinoma and pancreatic cancer cells. Finally, the capability of this platform as an in vivo MRI contrast agent is tested using a 3T scanner. The Gd(III) chelate was quickly cleaved by the blood pool thiols and eliminated through the renal excretion pathway. Further tuning of the Gd(III) chelate release kinetics is needed before the MSN system can be used as target-specific MRI contrast agents in vivo.

[1]  Jeremy L. Steinbacher,et al.  Gd-labeled microparticles in MRI: in vivo imaging of microparticles after intraperitoneal injection. , 2010, Small.

[2]  Wenbin Lin,et al.  Hybrid nanomaterials for biomedical applications. , 2010, Chemical Communications.

[3]  D. Parker,et al.  An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix. , 2010, Molecular pharmaceutics.

[4]  Ambika Bumb,et al.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. , 2010, Chemical reviews.

[5]  Taeghwan Hyeon,et al.  Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. , 2010, Journal of the American Chemical Society.

[6]  S. Eustace,et al.  Molecular and magnetic resonance imaging: The value of immunoliposomes. , 2009, Advanced drug delivery reviews.

[7]  T. Hyeon,et al.  Nanostructured T1 MRI contrast agents , 2009 .

[8]  Eun-Kee Jeong,et al.  Tumor Characterization with Dynamic Contrast Enhanced Magnetic Resonance Imaging and Biodegradable Macromolecular Contrast Agents in Mice , 2009, Pharmaceutical Research.

[9]  Taeghwan Hyeon,et al.  Inorganic Nanoparticles for MRI Contrast Agents , 2009 .

[10]  T. Meade,et al.  Magnetic Nanoparticles for Early Detection of Cancer by Magnetic Resonance Imaging , 2009, MRS bulletin.

[11]  Esther H Chang,et al.  Does a targeting ligand influence nanoparticle tumor localization or uptake? , 2008, Trends in biotechnology.

[12]  P. Choyke,et al.  Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. , 2008, Nanomedicine.

[13]  Wenbin Lin,et al.  Surfactant-assisted synthesis of nanoscale gadolinium metal-organic frameworks for potential multimodal imaging. , 2008, Angewandte Chemie.

[14]  Sam S. Chang,et al.  Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. , 2008, The Journal of urology.

[15]  P. Stratta,et al.  Gadolinium-enhanced magnetic resonance imaging, renal failure and nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy. , 2008, Current medicinal chemistry.

[16]  Chen Chang,et al.  High-contrast paramagnetic fluorescent mesoporous silica nanorods as a multifunctional cell-imaging probe. , 2008, Small.

[17]  Weili Lin,et al.  Mesoporous silica nanospheres as highly efficient MRI contrast agents. , 2008, Journal of the American Chemical Society.

[18]  E. Kanal,et al.  Gadolinium‐induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury , 2007, The British journal of dermatology.

[19]  M. Perazella,et al.  Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. , 2008, Current drug safety.

[20]  Tobias Schaeffter,et al.  Magnetic resonance imaging and spectroscopy. , 2008, Handbook of experimental pharmacology.

[21]  Zheng-Rong Lu,et al.  Polymer platforms for drug delivery and biomedical imaging. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Kathryn Trinkaus,et al.  Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy , 2007, Molecular Cancer.

[23]  Victor S-Y Lin,et al.  Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins. , 2007, Journal of the American Chemical Society.

[24]  Klaas Nicolay,et al.  MRI contrast agents: current status and future perspectives. , 2007, Anti-cancer agents in medicinal chemistry.

[25]  W. Cho,et al.  Nasopharyngeal carcinoma: molecular biomarker discovery and progress , 2007, Molecular Cancer.

[26]  Leaf Huang,et al.  Surface‐Modified LPD Nanoparticles for Tumor Targeting , 2006, Annals of the New York Academy of Sciences.

[27]  Dennis L Parker,et al.  Biodegradable cystamine spacer facilitates the clearance of Gd(III) chelates in poly(glutamic acid) Gd-DO3A conjugates for contrast-enhanced MR imaging. , 2006, Magnetic resonance imaging.

[28]  D. Parker,et al.  Pharmacokinetics, Biodistribution and Contrast Enhanced MR Blood Pool Imaging of Gd-DTPA Cystine Copolymers and Gd-DTPA Cystine Diethyl Ester Copolymers in a Rat Model , 2006, Pharmaceutical Research.

[29]  Weili Lin,et al.  Nanoscale metal-organic frameworks as potential multimodal contrast enhancing agents. , 2006, Journal of the American Chemical Society.

[30]  D. Parker,et al.  Effect of size and charge on pharmacokinetics and in vivo MRI contrast enhancement of biodegradable polydisulfide Gd(III) complexes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[31]  A. Mohs,et al.  Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents , 2006, International journal of nanomedicine.

[32]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[33]  Francesco M Veronese,et al.  PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.

[34]  Pradeep Tyagi,et al.  Anisamide‐targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells , 2004, International journal of cancer.

[35]  D. Parker,et al.  Extracellular biodegradable macromolecular gadolinium(III) complexes for MRI , 2004, Magnetic resonance in medicine.

[36]  Joel A Swanson,et al.  Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. , 2003, Advanced drug delivery reviews.

[37]  W. Bowen,et al.  Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. , 1999, Cancer research.

[38]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[39]  R. Hodges,et al.  A new heterobifunctional cross-linking reagent for the study of biological interactions between proteins. I. Design, synthesis, and characterization. , 1981, The Journal of biological chemistry.